Real-world longitudinal data on patients with cancer.
Through the course of over 15 years of clinically testing patient’s tumor responses to drugs, Helomics has amassed a huge proprietary knowledgebase of 150K+ cases. This data has been rigorously de-identified and aggregated to build a unique, proprietary model of tumor drug response that we call TumorSpace. The TumorSpace model and its data provide a priori knowledge for the machine learning approaches we employ as part of the PeDAL approach.
TumorSpace contains data from high-quality, standardized drug response data from clinical testing and has a rich diversity of data from hundreds of tumor types and subtypes. In addition, TumorSpace contains:
- Clinical & demographic information
- Biomarker and mutational profiles
And can access 10+ years of historical clinical outcome data.
Opportunity for additional data acquisition and access to historical patient outcomes.
In addition to the data within TumorSpace, Helomics has a large collection of archived FFPE blocks that under appropriate circumstances can be used for further data generation, such as Whole Genome, Whole Exome, and Whole Transcriptome sequencing.
We have demonstrated as part of our UPMC-Magee retrospective study that we can extract high-quality nucleic acid from our materials and generate robust Whole Exome and Whole Transcriptome data. As a clinical laboratory from which oncologists ordered testing, we can work with our historical clinicians and their facilities to obtain more patient outcome data. This offers a unique opportunity to sequence a tumor and very quickly have access to 10-plus years of survival data, without waiting for years to accumulate that information. As part of that same UPMC-Magee study, we have shown that we can indeed access this data to gain a clear picture of disease progression.
This provides a comprehensive tumor profile that includes:
- Tumor drug response
- Tumor pathology and clinical stage
- Tissue stains and biomarkers
- Whole Exome and Whole Transcriptome
- Patient treatment regimens, Patient outcome (Overall Survival
and Progression-Free Survival)